Health
Neurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to Antidepressants
Neurolief, a medical technology company developing neuromodulation therapies for mental health conditions, today announced a $6 million milestone-based investment from BrainsWay Ltd., following FDA Premarket Approval (PMA) of its Proliv™Rx brain neuromodulation system. The investment reflects growing recognition of the need for accessible, clinically validated treatment options for adults whose depression has not adequately improved with antidepressant medication.
About this update from Brainsway Ltd
[{"type":"text","content":"Investment accelerates U.S. rollout of a scalable, at-home brain neuromodulation therapy for patients with depression and inadequate response to at least one antidepressant","length":177,"tagName":"p"},{"type":"text","content":"CORAL SPRINGS, Fla., March 30, 2026 /PRNewswire/ -- Neurolief, a medical technology company developing neuromodulation therapies for mental health conditions, today announced a $6 million milestone-based investment from BrainsWay Ltd., following FDA Premarket Approval (PMA) of its Proliv™Rx brain neuromodulation system. The investment reflects growing recognition of the need for accessible, clinically validated treatment options for adults whose depression has not adequately improved with antidepressant medication.","length":520,"tagName":"p"},{"type":"image","alt":"Neurolief Proliv Rx","displaySize":"","headline":null,"caption":"Neurolief Proliv Rx","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/dd4019fe96e82c2ec00084dc9459ac20"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RdNtvh5P968jj7it.B5Gnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MQ--/https://media.zenfs.com/en/prnewswire.com/dd4019fe96e82c2ec00084dc9459ac20","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2945071/Brain_Therapy.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Millions of adults in the United States live with depression and do not achieve adequate response to antidepressant therapy. While several next-step treatment options exist, real-world access remains limited due to clinic-dependent delivery models, infrastructure requirements, referral delays, and logistical barriers that limit patient uptake.","length":345,"tagName":"p"},{"type":"text","content":"Proliv™Rx is a brain neuromodulation therapy designed for at-home use, addressing this critical treatment gap. FDA-approved in December 2025, the system is prescribed and supervised by a physician while being self-administered by the patient at home. This model expands access to next-step depression care for patients who are unable to reach specialized treatment centers, while maintaining the clinical oversight expected of prescription therapy.","length":448,"tagName":"p"},{"type":"text","content":""This investment enhances our ability to b...